Trial · NCT04150887
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
NCT04150887, Phase 1, Active not recruiting, OncoVerity, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia. Trials, record NCT04150887. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04150887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- NCT number
- NCT04150887
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 61 participants, actual
- Lead sponsor
- OncoVerity, Inc.
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Cusatuzumab, Azacitidine, Venetoclax
- First posted
- 2019-11-05
- Last updated
- 2026-05-12
- Other registries' IDs
- eudract:2019-002808-41
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of Safety | Up to 42 months | Frequency and severity of AEs, laboratory abnormalities, and physical exam findings will be reported. |
| Secondary | Serum Concentration of Cusatuzumab | Up to 23 months | Serum concentration of cusatuzumab will be assessed. |
| Secondary | Number of Participants with Anti-cusatuzumab Antibodies | Up to 23 months | Number of participants with anti-drug antibodies to cusatuzumab will be reported. |
| Secondary | Percentage of Participants with Complete Response (CR) | Up to 42 months | Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported. |
| Secondary | Percentage of Participants with Complete Remission with Partial Hematological Recovery (CRh) | Up to 42 months | Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment. |
| Secondary | Percentage of Participants with CR with Incomplete Recovery (CRi) | Up to 42 months | Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment. |
| Secondary | Percentage of Participants with CR plus CRh | Up to 42 months | Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment. |
| Secondary | Overall Response Rate (ORR) | Up to 42 months | ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment. |
| Secondary | Percentage of Participants with CR without MRD | Up to 42 months | Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than (\<) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level \<10\^-3). |
| Secondary | Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS) | Up to 42 months | Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as \< 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level \<10\^-3). |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04150887
GET https://conductscience.org/api/trials/v1/NCT04150887/registered